Ventfort vs Vesugen
Comparison of Ventfort (Very Low evidence) and Vesugen (Low evidence).
Last updated: February 12, 2026
Ventfort
Vesugen
Overview
Ventfort and Vesugen are both studied in the peptide research space.
Ventfort: A cytamin-class peptide supplement derived from blood vessel tissue, part of the Russian bioregulator framework.
Vesugen: A synthetic tripeptide (Lys-Glu-Asp) developed by Russian scientist Vladimir Khavinson, claimed to support vascular health by modulating endothelial gene expression.
Evidence Comparison
| Aspect | Ventfort | Vesugen |
|---|---|---|
| Evidence Level | Very Low | Low |
| Human Studies | 0 | 2 |
| Preclinical Studies | 5 | 8 |
| Total Sources | 6 | 12 |
Key Differences
| Aspect | Ventfort | Vesugen |
|---|---|---|
| Category | Other | Other |
| Evidence Strength | Very Low | Low |
| Total Sources | 6 | 12 |
| Human Studies | 0 | 2 |
Summary
- Ventfort: Very Low evidence with 6 total sources (0 human)
- Vesugen: Low evidence with 12 total sources (2 human)
This comparison is for educational purposes only and is not medical advice. Consult a healthcare professional before making any decisions about peptide use.
View Full Dossiers
Stay Updated on Peptide Comparisons
Get notified when we publish new comparison dossiers and evidence reviews.
No spam. Unsubscribe anytime.
Disclaimer: This comparison is for educational purposes only and does not constitute medical advice. Individual responses to medications vary. Always consult a qualified healthcare provider before making treatment decisions.